Hepatitis
Original Research
Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir
Hepatitis C virus-associated porphyria cutanea tarda can result from viral-induced inhibition of uroporphyrinogen...
Original Research
Outcomes Comparison of the Veterans’ Choice Program With the Veterans Affairs Healthcare System for Hepatitis C Treatment
The rates of cure at 12 weeks were similar between VA and Choice program providers and were comparable to the national average at the time, even...
Original Research
A Case-Based Review of Iron Overload With an Emphasis on Porphyria Cutanea Tarda, Hepatitis C, C282Y Heterozygosity, and Coronary Artery Disease
Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda,...
Latest News
HCV a risk in HIV-negative MSM who use PrEP
HIV-negative MSM on PrEP are at risk for HCV-infection, with risk-factors similar to those in HIV-positive MSM.
Conference Coverage
ED-based HCV screening found feasible, linkage low
BOSTON – Among patients with homes, linkage to care was 59%, compared with 20% for patients who were homeless.
Conference Coverage
Short-course DAA therapy may prevent hepatitis transmission in transplant patients
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
News
Hepatitis C vaccine alters viral trajectory, but fails in chronic infection protection
BOSTON – First-ever randomized study does suggest changes in peak HCV RNA and an HCV RNA change after infection.
Latest News
More evidence that statins reduce HCC risk
SAN ANTONIO – Largest-ever meta-analysis shows 43% relative risk reduction in HCC.
News
HCV testing/awareness successful as part of HIV integrated care
Conference Coverage
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...